Identification of the Novel Variants in Patients With Chronic Thromboembolic Pulmonary Hypertension

• Published in: Journal of the American Heart Association 2020-11, Vol.9 (21), p.e015902-e015902
• Main Authors: Yaoita, Nobuhiro, Satoh, Kimio, Satoh, Taijyu, Shimizu, Toru, Saito, Sakae, Sugimura, Koichiro, Tatebe, Shunsuke, Yamamoto, Saori, Aoki, Tatsuo, Kikuchi, Nobuhiro, Kurosawa, Ryo, Miyata, Satoshi, Nagasaki, Masao, Yasuda, Jun, Shimokawa, Hiroaki
• Format: Article
• Language: English
• Subjects: Acute Disease; Aged; Aged, 80 and over; Asian Continental Ancestry Group - genetics; Carboxypeptidase B2 - genetics; Chronic Disease; chronic thromboembolic pulmonary hypertension; Factor V - genetics; Female; Gene Frequency - genetics; gene variants; Genetic Variation - genetics; Humans; Hypertension, Pulmonary - complications; Hypertension, Pulmonary - genetics; Japan; Male; Middle Aged; Original Research; Pulmonary Embolism - complications; Pulmonary Embolism - genetics; pulmonary hypertension; Thrombomodulin - genetics; Whole Exome Sequencing
• ISSN: 2047-9980; 2047-9980
• DOI: 10.1161/JAHA.120.015902

Background Although chronic thromboembolic pulmonary hypertension (CTEPH) and acute pulmonary embolism (APE) share some clinical manifestations, a limited proportion of patients with CTEPH have a history of APE. Moreover, in histopathologic studies, it has been revealed that pulmonary vasculature lesions similar to pulmonary arterial hypertension existed in patients with CTEPH. Thus, it remains unknown whether these 3 disorders also share genetic backgrounds. Methods and Results Whole exome screening was performed with DNA isolated from 51 unrelated patients with CTEPH of Japanese ancestry. The frequency of genetic variants associated with pulmonary arterial hypertension or APE in patients with CTEPH was compared with those in the integrative Japanese Genome Variation Database 3.5KJPN. Whole exome screening analysis showed 17 049 nonsynonymous variants in patients with CTEPH. Although we found 6 nonsynonymous variants that are associated with APE in patients with CTEPH, there was no nonsynonymous variant associated with pulmonary arterial hypertension. Patients with CTEPH with a history of APE had nonsynonymous variants of , which encodes factor V. In contrast, patients with CTEPH without a history of APE had a nonsynonymous variant of , which encodes thrombomodulin. Moreover, thrombin-activatable fibrinolysis inhibitor, which is one of the pathogenic proteins in CTEPH, was significantly more activated in those who had the variants of compared with those without it. Conclusions These results provide the first evidence that patients with CTEPH have some variants associated with APE, regardless of the presence or absence of a history of APE. Furthermore, the variants might be different between patients with CTEPH with and without a history of APE.